Tag:
BioMS Medical
Latest Headlines
Latest Headlines
Lilly, BioMS shutter MS drug program
A Phase III trial for an experimental new drug for multiple sclerosis backed by Eli Lilly and BioMS Medical failed to hit its primary endpoint and several secondary endpoints in a late-stage trial,
BioMS stocks plunge on failed trial
BioMS Medical shares plunged more than 30 percent today on the news that its phase II trial MINDSET-01--designed to evaluate dirucotide in patients with relapsing-remitting multiple sclerosis--did
BioMS wins $10M milestone on pivotal trial progress
According to BioMS Medical, an independent monitoring board has recommended that a phase II/III study of dirucotide (MBP8298) in patients with secondary progressive MS should continue to completion.
